Cambrex Co. (CBM) Forecasted to Earn FY2017 Earnings of $2.96 Per Share
Cambrex Co. (NYSE:CBM) – Stock analysts at William Blair issued their FY2017 earnings per share (EPS) estimates for Cambrex in a research note issued to investors on Tuesday. William Blair analyst J. Kreger anticipates that the biotechnology company will post earnings of $2.96 per share for the year. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Cambrex’s Q4 2017 earnings at $1.09 EPS, FY2018 earnings at $2.95 EPS, FY2019 earnings at $3.13 EPS, FY2020 earnings at $3.32 EPS and FY2021 earnings at $3.61 EPS.
CBM has been the topic of a number of other reports. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday. Craig Hallum reissued a “buy” rating and issued a $60.00 target price (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $60.50.
Cambrex (NYSE:CBM) last released its earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.47 by $0.08. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The business had revenue of $112.60 million for the quarter, compared to analyst estimates of $108.44 million. During the same period last year, the company posted $0.47 EPS. The business’s revenue was up 13.4% on a year-over-year basis.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CBM. Schwab Charles Investment Management Inc. lifted its stake in Cambrex by 3.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 150,109 shares of the biotechnology company’s stock worth $8,970,000 after purchasing an additional 4,582 shares in the last quarter. Swiss National Bank raised its position in shares of Cambrex by 2.8% during the 2nd quarter. Swiss National Bank now owns 54,400 shares of the biotechnology company’s stock valued at $3,250,000 after buying an additional 1,500 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Cambrex by 29.9% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,781 shares of the biotechnology company’s stock valued at $525,000 after buying an additional 2,020 shares during the period. Riverhead Capital Management LLC raised its position in shares of Cambrex by 90.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,264 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of Cambrex by 3.4% during the 2nd quarter. Teachers Advisors LLC now owns 353,138 shares of the biotechnology company’s stock valued at $21,100,000 after buying an additional 11,592 shares during the period.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.